Q-omics provides the consensus-scored TSTD1 profile across patient tissues and cancer cell-line models. TSTD1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TSTD1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TSTD1 protein abundance shows 22,789 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LGG, KICH, and LUAD as cancer lineages where TSTD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSTD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSTD1 survival associations across molecular data types. TSTD1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSTD1 RNA expression–survival associations across cancer types. High TSTD1 expression shows unfavorable associations in LGG and ESCA, but favorable associations in MESO, LUAD, SARC and THCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TSTD1 RNA expression.
This table summarizes TSTD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSTD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSTD1 shows lower tumor expression in KICH, KIRC, LUSC and KIRP and higher tumor expression in BLCA and BRCA. The KICH box plot shows higher TSTD1 RNA expression in normal versus tumor tissue (log2 FC = −1.989, t-test p < 0.001).
This table shows molecular features associated with TSTD1 in patient tissues and cancer cell lines. In patient samples, TSTD1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TSTD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
